Literature DB >> 20090510

Membranous (class V) renal disease in systemic lupus erythematosus may be more common than previously reported: results of a 6-year retrospective analysis.

Sumeet Bhinder1, Amrit Singh, Vikas Majithia.   

Abstract

BACKGROUND: The actual incidence and prevalence of the various histological classes (based on World Health Organization classification) of lupus nephritis (LN) are not known but seem to vary with sex, age, and ethnicity. We have analyzed renal biopsies in patients with systemic lupus erythematosus (SLE) at our center, and hereby report our experience.
METHODS: All renal biopsies performed at the University of Mississippi between January 1999 and December 2004 in patients with SLE were retrospectively analyzed. Results were validated by a detailed review of renal biopsy reports and additional records were reviewed for data specific to LN disease activity.
RESULTS: There were 92 renal biopsies performed in patients with SLE during a 6-year period. These included 84 African Americans (72 women and 12 men), 5 whites (4 women and 1 man), and 3 unknown race (1 F, 2 M) subjects. The prevalence of LN classes in our cohort was as follows: class I (0%), class II (9.8%), class III (8.7%), class IV (36.9%), class V (40.2%), and class VI (4.3%). Prevalence of class V LN among males was high at 40%.
CONCLUSION: In contrast to previous literature, isolated membranous lupus nephritis (MLN) was much more prevalent in this series-40% versus 14%. Also, no sex difference in the prevalence of MLN was seen. This biopsy cohort suggests that MLN/class V disease may be more common than previously reported especially in African American population.

Entities:  

Mesh:

Year:  2010        PMID: 20090510     DOI: 10.1097/MAJ.0b013e3181c9529c

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  5 in total

1.  Autoantibodies targeting glomerular annexin A2 identify patients with proliferative lupus nephritis.

Authors:  Dawn J Caster; Erik A Korte; Michael L Merchant; Jon B Klein; Daniel W Wilkey; Brad H Rovin; Dan J Birmingham; John B Harley; Beth L Cobb; Bahram Namjou; Kenneth R McLeish; David W Powell
Journal:  Proteomics Clin Appl       Date:  2015-06-12       Impact factor: 3.494

Review 2.  UCH-L1 Expressed by Podocytes: a Potentially Therapeutic Target for Lupus Nephritis?

Authors:  Ji-Hong Cui; Xin Xie
Journal:  Inflammation       Date:  2017-04       Impact factor: 4.092

Review 3.  Contributions of mass spectrometry-based proteomics to defining cellular mechanisms and diagnostic markers for systemic lupus erythematosus.

Authors:  Erik A Korte; Patrick M Gaffney; David W Powell
Journal:  Arthritis Res Ther       Date:  2012-02-20       Impact factor: 5.156

4.  Resolution of C1q deposition but not of the clinical nephrotic syndrome after immunomodulating therapy in focal sclerosis.

Authors:  Tibor Tibor Fülöp; Éva Csongrádi; Anna A Lerant; Matthew Lewin; Jack R Lewin
Journal:  J Nephropathol       Date:  2015-04-01

5.  Patients with Proliferative Lupus Nephritis Have Autoantibodies That React to Moesin and Demonstrate Increased Glomerular Moesin Expression.

Authors:  Dawn J Caster; Erik A Korte; Michael L Merchant; Jon B Klein; Michelle T Barati; Ami Joglekar; Daniel W Wilkey; Susan Coventry; Jessica Hata; Brad H Rovin; John B Harley; Bahram Namjou-Khales; Kenneth R McLeish; David W Powell
Journal:  J Clin Med       Date:  2021-02-16       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.